In conclusion, while the number of SMN2 gene copies significantly determines SMA severity, our research indicates that the quality of these copies and other genetic factors play a crucial role, emphasising the need for a comprehensive assessment considering both the quantity and quality of SMN2 copies and the identification of other potential genetic modifiers for improved disease prediction and management. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.